Salesforce.com to B...
Health Care: Drugs
Exelixis Inc. (EXEL: NASDAQ)
$4.52 0.04 | 1.01%
06/04/12 - 12:30 PM ET
Company Balance Sheet
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 74.26M | 97.44M | 86.80M | 247.70M |
| Receivables | 30.19M | 5.90M | 11.86M | 1.46M |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 228.82M | 183.49M | 230.00M | 271.57M |
| Property, Plant & Equipment, Gross | 59.88M | 90.66M | 134.17M | 129.99M |
| Accumulated Depreciation & Depletion | 51.38M | 74.85M | 104.78M | 93.74M |
| Property, Plant & Equipment, Net | 8.51M | 15.81M | 29.39M | 36.25M |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 92.25M | 97.81M | 20.33M | 30.12M |
| Total Non-Current Assets | 164.44M | 177.30M | 113.41M | 130.05M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 393.26M | 360.79M | 343.41M | 401.62M |
| Accounts Payable | 1.96M | 2.05M | 7.40M | 4.95M |
| Short Term Debt | 0.00 | 28.90M | 28.05M | 28.05M |
| Other Current Liabilities | 4.48M | 0.00 | 0.00 | 0.00 |
| Total Current Liabilities | 92.32M | 199.94M | 207.12M | 189.54M |
| Long Term Debt | 176.64M | 170.71M | 40.36M | 74.72M |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 33.66M | 218.46M | 259.65M | 193.62M |
| Minority Interest | 0.00 | 0.00 | -4.34M | -12.72M |
| Total Non-Current Liabilities | 210.30M | 389.17M | 300.02M | 269.05M |
| Total Liabilities | 302.63M | 589.12M | 507.14M | 458.60M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 90.63M | -228.32M | -163.72M | -56.98M |
| Common Par | 135.00K | 109.00K | 108.00K | 106.00K |
| Additional Paid In Capital | 1.20B | 953.61M | 925.74M | 897.42M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -1.11B | -1.18B | -1.09B | -954.50M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | -138.00K | 12.00K | 155.00K | 0.00 |
| Total Capitalization | 267.28M | -57.62M | -123.36M | 17.74M |
| Total Equity | 90.63M | -228.32M | -163.72M | -56.98M |
| Total Liabilities & Stock Equity | 393.26M | 360.79M | 343.41M | 401.62M |
| Total Common Shares Outstanding | 148.42M | 109.29M | 107.92M | 106.33M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 126.02M | 108.52M | 107.07M | 105.50M |
| Diluted Weighted Shares Outstanding | 130.48M | 108.52M | 107.07M | 105.50M |
| Number of Employees | 200 | 240 | 676 | 676 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with EXEL
- Portfolio NameUser Type
- Contributor10 Stocks That Could Rise i...
- Contributor10 Biotech Stocks Loved and...
- Contributor10 Biotech Trades for Secon...
- UserMy Portfolio
- ContributorCancer Drug Stocks to Trade...
- Userbarry216 Portfolio 1
- UserSUPRATRADE HOT STOCKS (BUY ...
- UserASCO 2010
- UserBartwaldon Portfolio 1
- UserPART 3 JPMorgan 28th Annual...
Latest EXEL Headlines from TheStreet
- ASCO 2012 Live Blog -- Sunday 06.03.12 | 07:06 am
- ASCO 2012 Live Blog -- Saturday 06.02.12 | 07:06 am
- Exelixis' Management Presents At Bank Of America Merrill Lynch 2012 Health Care Conference (Transcript) 05.17.12 | 06:05 pm
- ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update) 05.17.12 | 06:05 am
- ASCO '12 Abstract Dump: Cancer Stocks in Focus 05.16.12 | 06:05 pm
- Exelixis' Management Presents At Deutsche Bank Securities Annual Health Care Conference (Transcript) 05.09.12 | 08:05 pm
- Friday's Top 10 Articles, Videos on TheStreet 05.04.12 | 01:05 pm
- Biotech Stock Mailbag: Exelixis, Protalix, Arena 05.04.12 | 07:05 am
- Exelixis's CEO Discusses Q1 2012 Results - Earnings Call Transcript 05.03.12 | 10:05 pm
- 10 Stocks That Could Rise in Market Decline 04.10.12 | 07:04 am
Press Releases for EXEL
- Cabozantinib Meets Primary Endpoint Of Progression Free Survival In Phase 3 Pivotal Trial In Medullary Thyroid Cancer - Business Wire 06.04.12 | 12:06 pm
- Cabozantinib Demonstrates Evidence Of Anti-Tumor Effects In Heavily Pretreated Patients With Hepatocellular Carcinoma - Business Wire 06.02.12 | 06:06 pm
- Cabozantinib Demonstrates Encouraging Activity In Patients With Heavily Pretreated Metastatic Renal Cell Carcinoma - Business Wire 06.02.12 | 05:06 pm
- Exelixis Announces June 6th Webcast Of Presentation At The Goldman Sachs 33rd Annual Global Healthcare Conference - Business Wire 05.31.12 | 05:05 pm
- Exelixis Initiates COMET-1 Pivotal Trial Focused On Overall Survival In Men With Advanced Prostate Cancer - Business Wire 05.30.12 | 06:05 am
- Exelixis Completes Submission Of New Drug Application For Cabozantinib For The Treatment Of Medullary Thyroid Cancer - Business Wire 05.30.12 | 06:05 am
- Reminder: Exelixis Announces Data Presentations, Webcast Of Investor Briefing In Conjunction With 2012 ASCO Annual Meeting - Business Wire 05.16.12 | 06:05 am
- Exelixis Expands The Cabozantinib Development Program Through NCI-CTEP Collaboration - Business Wire 05.03.12 | 06:05 am
- Exelixis Announces May 8th Webcast Of Presentation At The Deutsche Bank Securities 37th Annual Health Care Conference - Business Wire 05.02.12 | 04:05 pm
- Exelixis Announces May 3rd Webcast Of First Quarter 2012 Financial Results Conference Call - Business Wire 04.19.12 | 04:04 pm
Partner Headlines for EXEL
- Cabozantinib Demonstrates Evidence of Anti-Tumor Effects in Heavily Pretreated Patients with Hepatocellular Carcinoma - Benzinga 06.02.12 | 06:06 pm
- Biotech Stocks To Watch In 2012 - Seeking Alpha 02.06.12 | 09:02 am
- 5 Biotech Stocks That Could Double - Seeking Alpha 02.01.12 | 07:02 am
- UPDATE: Piper Jaffray Downgrades Exelixis to Neutral - Benzinga 11.01.11 | 09:11 am
- Notable Put Options Activity in Exelixis - Benzinga 10.28.11 | 01:10 pm
- 3 Biotech Takeover/LBO Targets With Bullish Short Trends - Seeking Alpha 10.26.11 | 09:10 am
- 7 Possible Biotech Takeover Targets - Seeking Alpha 09.18.11 | 08:09 am
- Biotech Gem Exelixis Is Compelling Only for the Long Term - Seeking Alpha 08.19.11 | 05:08 pm
- 5 Biotech Takeover / LBO Targets With Bullish Short Trends - Seeking Alpha 07.15.11 | 07:07 pm
- Exelixis extends timeline for thyroid cancer data - Reuters 07.06.11 | 04:07 pm
